Valuation: Colinz Laboratories Limited

Market Cap 189M 1.97M 1.71M 1.61M 1.46M 2.74M 2.76M 19.25M 7.42M 95.85M 7.4M 7.24M 305M P/E 2025
36.8x
P/E 2026 21.8x
Enterprise Value 108M 1.12M 972K 917K 832K 1.56M 1.57M 10.96M 4.22M 54.56M 4.21M 4.12M 173M EV / Sales 2025
2.04x
EV / Sales 2026 0.5x
Free-Float
31.44%
Yield 2025 *
-
Yield 2026 -
30/07 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar executed of Share Purchase Agreement to acquire an additional 34.56% stake in Colinz Laboratories Limited from Vijaya Mani for INR 43.5 million, CI
18/06 Annjana Dugar, Likhitta Dugar and Antariksh Dugar proposed to acquire an additional 26% stake in Colinz Laboratories Limited for INR 35.4 million. CI
25/05 Padam Dugar, Annjana Dugar, Likhitta Dugar and Antariksh Dugar acquired 15.01% stake in Colinz Laboratories Limited. CI
29/04 Colinz Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
24/01 Colinz Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
17/01 Hilsun Foods And Drugs Private Limited signed a letter of intent to acquire Factory Building, Factory Machinery, & Factory Land of Colinz Laboratories Limited for INR 40 million. CI
27/11 Colinz Laboratories Limited Appoints Falguni Kumawat as Company Secretary and Compliance Officer, with Effect from 1 December, 2025 CI
08/11 Colinz Laboratories Limited Announces of Demise Dr. Mani L.S., Founder Director, Company Secretary and Compliance Officer on 7 November 2025 CI
03/11 Colinz Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
31/07/25 Colinz Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
21/05/25 Colinz Laboratories Limited Appoints Swapnil Jayesh Madiyar as Additional Director, Effective from May 16, 2025 CI
16/05/25 Colinz Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
1 day+3.45%
1 week-1.55%
Current month+4.65%
1 month-6.10%
3 months+37.16%
6 months+81.29%
Current year+39.85%
1 week 69.5
Extreme 69.5
75.99
1 month 68.89
Extreme 68.89
84
Current year 39.31
Extreme 39.31
87.91
1 year 36.11
Extreme 36.11
87.91
3 years 35.2
Extreme 35.2
88.7
5 years 16.6
Extreme 16.6
88.7
10 years 4.8
Extreme 4.8
88.7
Manager TitleAgeSince
Chief Executive Officer 74 -
Director of Finance/CFO - 20/05/2019
Compliance Officer - 01/12/2025
Director TitleAgeSince
Director/Board Member 74 26/11/1990
Director/Board Member 33 08/08/2024
Director/Board Member 76 08/08/2024
Change 5-day change 1-year change 3-year change Capi.($)
+3.45%-1.55%+84.55%+91.86% 1.91M
-0.27%-3.17%+13.51%+60.43% 46.06B
+1.42%-2.60%+34.32%+109.71% 38.29B
-1.80%-5.00%+5.19%+71.75% 11.65B
-1.10%-3.15%-14.20%+9.50% 11.51B
-0.95%-0.76%+18.18%+146.45% 9.17B
+0.80%+0.64%+24.85%+37.61% 7.22B
-1.96%-3.27%+11.22%+174.06% 7.12B
+0.68%-2.69%+36.28%-18.66% 7.11B
-2.15%-5.49%-45.74%+9.75% 4.99B
Average -0.22%-2.02%+16.82%+69.25% 14.31B
Weighted average by Cap. -0.12%-2.67%+15.99%+74.76%

Financials

2025 2026
Net sales 65.28M 681K 590K 557K 505K 948K 955K 6.65M 2.56M 33.11M 2.56M 2.5M 105M 61.36M 640K 555K 523K 475K 891K 897K 6.25M 2.41M 31.13M 2.4M 2.35M 98.96M
Net income 4.97M 51.81K 44.9K 42.37K 38.44K 72.1K 72.63K 506K 195K 2.52M 195K 190K 8.01M 5.14M 53.68K 46.51K 43.9K 39.82K 74.7K 75.24K 524K 202K 2.61M 202K 197K 8.3M
Net Debt -49.09M -512K -444K -419K -380K -713K -718K -5M -1.93M -24.9M -1.92M -1.88M -79.18M -81.39M -849K -736K -694K -630K -1.18M -1.19M -8.29M -3.2M -41.29M -3.19M -3.12M -131M
Logo Colinz Laboratories Limited
Colinz Laboratories Ltd. is an India-based company that is engaged in the manufacturing and marketing of pharmaceutical formulations, particularly in the gynecological sector. It is engaged in the manufacturing and marketing various allopathic, ayurvedic, and nutraceuticals pharmaceutical formulations in the dosage forms of tablets, capsules, liquid orals and ointments, among others. The company has specialized products for Gynecology, cardiology, gastroenterology, and others. Its oncology products include imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, and doxorubicin. Its Ayurvedic products include anti-diarrhoeals, anti-pyretics, anti-inflammatories, anti-spasmodics, cough syrups, appetite stimulating agents, and memory boosters. Its nutraceuticals products include spirulina tabs/caps, spirulina with vitamins & minerals, omega 3 fatty acid caps in softgel, codliver oil with vitamin caps in soft gel, collagen, and glucosamine & chondroitin tabs.
Employees
62
Date Price Change Volume
15/09/26 INR 75.00 +3.45% 1,793
11/09/26 INR 72.50 0.00% 4,144
10/09/26 INR 72.50 -0.01% 892
09/09/26 INR 72.51 -0.67% 2,156
08/09/26 INR 73.00 -4.17% 1,910
  1. Stock Market
  2. Stocks
  3. COLINZ6 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!